Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs IONS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYRE Captures Overall Composite Edge (36.1 SELL vs 60.4 BUY), While IONS Leads 4–2 on Growth & Valuation Pillars

SYRE Overall Winner 6-Pillar Tally: SYRE 2 – 4 IONS Matrix Metrics: SYRE 6 – 4 IONS

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Ionis Pharmaceuticals, Inc. (IONS) on higher Unified Composite conviction (36.1/100 SELL vs. 60.4/100 BUY) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IONS wins 4–2 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.97 (N/M Forward P/E, 0.0% operating margin) versus IONS at $28.57 (90.9x Forward P/E, -58.8% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (60.4/100 BUY vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -58.8% operating margin) and revenue trajectory (+0.0% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs IONS
SYRE NASDAQ Head-to-Head Winner
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $98.90 · SMA50: $91.75
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
60.4 / 100 BUY
Tech 60.0 Fund 62.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 24.1 · SMA20: $38.48 · SMA50: $43.08

6-Pillar Scorecard Institutional Category Breakdown (SYRE 2 – 4 IONS)

Columns: Metric · SYRE · IONS
1. Valuation Multiples IONS
Forward P/E N/M 90.9x
Trailing P/E N/M 90.9x
PEG Ratio N/M N/M
EV / Revenue N/M 6.2x
2. Growth & Scale IONS
Revenue Growth (YoY) +0.0% +54.9%
Earnings Growth (YoY) -99.7% -43.7%
TTM Revenue (USD) N/A $960M
Market Cap $9.8B $4.7B
3. Profitability & Quality SYRE
Gross Margin N/A 3.0%
Operating Margin 0.0% -58.8%
Net Profit Margin 0.0% -56.9%
Return on Equity (ROE) -35.0% -108.0%
4. Balance Sheet & Cash Flow IONS
Cash Generation (TTM) N/A -$623M
Cash Flow Margin N/A -64.9%
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE $1.33B Net Debt (4.14x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SYRE
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 87.9% (10th %ile) 59.9% (17th %ile)
Put/Call OI Skew N/A 1.81x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity N/A 61.8% of Rev ($593M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (6) vs IONS (4)
Institutional Metric SYRE IONS Criterion Row Edge
Market Capitalization
Scale
$9.8B $4.7B Larger Scale SYRE
Trailing P/E Ratio
Valuation
N/M 90.9x Lower Multiple IONS
Forward P/E Ratio
Valuation
N/M 90.9x Lower Multiple IONS
Revenue Growth (YoY)
Growth
+0.0% +54.9% Higher Growth IONS
Operating Margin (TTM)
Profitability
0.0% -58.8% Higher Margin SYRE
Net Profit Margin
Profitability
0.0% -56.9% Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
-35.0% -108.0% Higher ROE SYRE
52-Week Range Position
Momentum
88% ($22–$111) 2% ($27–$87) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.75β · 59% Vol 0.18β · 86% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
36.1 / 100 (SELL) 60.4 / 100 (BUY) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
N/A $960M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 3.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) -$623M ($1.33B Net Debt (4.14x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +58.59 pp
SYRE: +25.11% · IONS: -33.48%
3M Horizon SYRE +44.8 pp
SYRE: -7.29% · IONS: -52.09%
6M Horizon SYRE +103.25 pp
SYRE: +42.64% · IONS: -60.61%
1Y Horizon SYRE +400.84 pp
SYRE: +341.74% · IONS: -59.1%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs IONS. Trailing 12-month operating profitability (SYRE 0.0% vs IONS -58.8%) and valuation multiples (SYRE N/M vs IONS 90.9x Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
IONS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$960M
Gross Margin3.0%
Op. Margin-58.8%
ROE / Fwd P/E-108.0% · 90.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published

Investor FAQ SYRE vs IONS Key Questions & Quantitative Answers

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Ionis Pharmaceuticals, Inc. (IONS) on higher Unified Composite conviction (36.1/100 SELL vs. 60.4/100 BUY) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IONS wins 4–2 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.97 (N/M Forward P/E, 0.0% operating margin) versus IONS at $28.57 (90.9x Forward P/E, -58.8% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (60.4/100 BUY vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -58.8% operating margin) and revenue trajectory (+0.0% vs. +54.9% YoY). Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IONS leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IONS at +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $960M for IONS. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus 61.8% of Rev ($593M) (0 disclosures) for IONS.

IONS screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus IONS (-108.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.